Vactosertib or linivonib and application of combination of Vactosertib and linivonib in preparation of medicine for treating asthma
By combining Vactosertib or linivarib with nanotechnology, targeted delivery to the lungs using stem cell preparations, the problem of insufficient lung targeting and major side effects of drugs in the body in the prior art is solved, and effective for severe asthma is achieved Treatment and lung function recovery.
Patent Information
- Application Number
- CN202411056048.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-19
AI Technical Summary
The existing treatment plans cannot effectively treat severe asthma patients, especially because Vactosertib and linivarib have weak lung targeting and have large side effects in the body. Direct combination of use may cause serious adverse reactions, and the effect of treatment on asthma has not been found. Literature reports.
A stem cell preparation was designed to combine Vactosertib or linivarib with nanoformulations, using the homing properties of mesenchymal stem cells to target the preparation to the bronchial site of the lungs and responsively release drugs in a high reactive oxygen environment. , inhibits airway remodeling and inflammation, forms polymer micelles of PLGA5000-TK-PEG2000, PLGA5000-TK-PEG2000-Mal, Vactosertib and Linivarib, and combines stem cells to create high-targeted and low-toxic drug delivery system.
Effective treatment of severe asthma is achieved, through targeted delivery of drugs to damaged bronchial sites, inhibit subepithelial fibrosis and angiogenesis, reverse airway remodeling, reduce the toxic side effects of drugs, and significantly improve the lung function of asthma patients.
Smart Images

Figure CN118976025A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of pharmaceutical preparations, and in particular relates to the application of Vactosertib or Linifanib and the combination of the two in the preparation of asthma treatment drugs. Background Art
[0002] Asthma is a chronic respiratory disease characterized by wheezing and shortness of breath. Its pathological features are chronic bronchial inflammation, airway remodeling and airway hyperresponsiveness. Current clinical treatments mainly focus on temporarily controlling symptoms and relieving acute asthma attacks through anti-inflammatory or combined bronchodilators. However, since patients with severe asthma have a poor response to glucocorticoids, long-term use will produce many adverse reactions, so there is an urgent need to develop effective strategies to address these problems.
[0003] Vactosertib (TEW-7197, EW-7197, VST) is a highly potent, selective and orally bioavailable inhibitor of the TGF-β receptor ALK4 / ALK5; it has potential anti-tumor activity. When administered orally, Vactosertib inhibits the activity of TGFBR1 and blocks TGF-β / TGFBR1-mediated signaling. This inhibits tumor growth in TGFBR1-overexpressing tumor cells. TGFBR1 is overexpressed in a variety of tumor cell types and plays a key role in tumor cell proliferation. The expression of TGF-β promotes tumor cell proliferation, enhances tumor cell migration, and inhibits the host immune system's response to tumor cells.
[0004] Linifanib (ABT-869, LFN) is a novel and effective inhibitor of receptor tyrosine kinases (RTKs), vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) used to treat various cancers.
[0005] The above two drugs mainly have anti-tumor activity, and there is no literature report on their combined use in the treatment of severe asthma. Secondly, the dual drugs have weak lung targeting in vivo and large side effects, and direct combination may cause serious adverse reactions. Summary of the invention
[0006] Purpose of the invention: To solve the problem that current treatment options cannot treat patients with severe asthma, the present invention designs a stem cell preparation for treating asthma airway remodeling.
[0007] Technical solution: To solve the above problems, the technical solution adopted by the present invention is as follows:
[0008] The use of vactosertib or linifanib and the combination of the two in the preparation of drugs for treating asthma.
[0009] The asthma is severe asthma.
[0010] The application of stem cell preparations formed by the combination of Vactosertib and Linifanib in the preparation of drugs for the treatment of asthma.
[0011] Furthermore, the stem cell preparation includes nano preparations and mesenchymal stem cells.
[0012] Furthermore, the nanoformulation is a nanoformulation that encapsulates drugs that inhibit airway remodeling, and the nanocarrier is composed of PLGA 5000 -TK-PEG 2000 , PLGA 5000 -TK-PEG 2000 -Mal, A6 peptide and asthma treatment drugs.
[0013] Furthermore, the A6 peptide on the surface of the nanoformulation can specifically bind to the CD44 receptor on the surface of mesenchymal stem cells.
[0014] Furthermore, the mesenchymal stem cells are derived from adipose-derived mesenchymal stem cells, bone marrow-derived mesenchymal stem cells or umbilical cord-derived mesenchymal stem cells.
[0015] Furthermore, the mesenchymal stem cells can utilize their homing properties to deliver the preparation to the bronchial area of the lungs and regulate airway inflammation.
[0016] Furthermore, the thioketal bonds in the polymer micelles can react with and break ROS that are highly expressed in the airway, resulting in responsive drug release.
[0017] Furthermore, the method for preparing the stem cell preparation is characterized by comprising the following steps:
[0018] (1)PLGA 5000 -TK-PEG 2000 , PLGA 5000 -TK-PEG 2000 -Mal, Vactosertib and Linifanib were dissolved in DMSO, mixed and dispersed in 5% glucose solution.
[0019] (2) The dispersion was ultrasonically disrupted by an ultrasonic disruptor and incubated with A6 peptide to prepare a nanoformulation.
[0020] (3) The prepared nano preparation is co-incubated with mesenchymal stem cells to obtain a stem cell preparation.
[0021] Furthermore, the nanoformulation is characterized in that PLGA 5000 -TK-PEG 2000 , PLGA 5000 -TK-PEG 2000 -Mal was dissolved in DMSO at a concentration of 100-150 mg / mL, and Vactosertib and Linifanib were dissolved in DMSO at a concentration of 10-15 mg / mL. Optimal formulation of PLGA 5000 -TK-PEG 2000 , PLGA 5000 -TK-PEG 2000 The mass ratio of -Mal, Vactosertib and Linifanib is 30:20:2:1.
[0022] Furthermore, the stem cell preparation is characterized in that it is administered intravenously and can effectively accumulate in damaged bronchial areas, inhibit bronchial airway remodeling in asthma patients, prevent disease progression and treat severe asthma.
[0023] The present invention is a stem cell preparation carrying dual drugs. The homing effect of stem cells causes the preparation to accumulate in large quantities in the damaged lungs. The stem cell preparation utilizes the highly active oxygen environment in the pathological site to responsively release drugs, inhibit subepithelial fibrosis and angiogenesis, thereby reversing bronchial airway remodeling and treating chronic persistent asthma.
[0024] The innovation of the present invention is that Vactosertib and Linifanib are used as anti-tumor drugs. The present invention is the first to find that Vactosertib or Linifanib and the combination of the two are effective for asthma, which has not been reported in the literature. Specifically:
[0025] For the first time, Vactosertib and Linifanib were made into polymer micelles using nanotechnology and combined with stem cells to make stem cell preparations. Through intravenous administration, mesenchymal stem cells can be targeted to damaged bronchial sites, and polymer micelles respond to the highly reactive oxygen environment in the pathological site to release drugs, inhibit subepithelial fibrosis and angiogenesis, thereby reversing airway remodeling, preventing disease exacerbation and treating chronic persistent asthma.
[0026] Specifically: the stem cell preparation is composed of mesenchymal stem cells and nanopreparations combined through receptor-ligand interactions. The present invention uses mesenchymal stem cells as delivery carriers to achieve efficient drug delivery and treat severe asthma by reversing airway remodeling. The stem cell preparation migrates to the damaged bronchi under the action of inflammatory tropism. In the microenvironment of highly active oxygen in the lungs, the stem cells and nanopreparations separate and release the drugs. Vactosertib and linifanib inhibit the occurrence of airway remodeling by inhibiting subepithelial fibrosis and angiogenesis; mesenchymal stem cells reduce inflammatory cell infiltration and cytokine secretion, regulate the normalization of the pathological microenvironment, and thus effectively treat asthma.
[0027] Beneficial Effects
[0028] Compared with the prior art, the present invention has the following significant advantages:
[0029] 1. Vactosertib and linifanib are anti-tumor drugs. The present invention is the first to find that Vactosertib or linifanib and the combination of the two are effective for asthma, which has not been reported in the literature.
[0030] 2. Vactosertib and linifanib, as anti-tumor drugs, have large toxic and side effects. Secondly, as for asthma, the drugs need to be delivered to the lungs, but both cannot directly target the lungs. Therefore, the present invention uses nanotechnology to make polymer micelles and combines them with stem cells to make stem cell preparations, targeting the site of bronchial inflammation and responsively releasing drugs, inhibiting subepithelial fibrosis and angiogenesis, thereby inhibiting bronchial airway remodeling, thereby achieving effective treatment for patients with severe asthma, and providing new ideas for asthma treatment strategies targeting bronchial sites. Polymer micelles have low toxicity and high stability. The core of the micelle can be loaded with a large amount of hydrophobic drugs, improve the solubility of the drug and reduce toxic and side effects. Mesenchymal stem cells can regulate the immune microenvironment, relieve inflammation in the bronchial site, achieve a synergistic therapeutic effect, and have a good therapeutic effect on severe asthma. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1 This is a schematic diagram of the process for preparing the stem cell preparation of the present invention.
[0032] Figure 2 This is a particle size diagram of the nanoformulation in Example 1.
[0033] Figure 3 This is a laser confocal image of the stem cell preparation in Example 1.
[0034] Figure 4 The accumulation of the stem cell preparation in the lungs in Example 2, wherein A: in vivo imaging, B: ex vivo imaging.
[0035] Figure 5The in vitro cell efficacy of the stem cell preparation in Example 3, wherein A: fibroblasts, B: pulmonary microvascular endothelial cells.
[0036] Figure 6 Pathological sections of airway remodeling in severe asthma treated with different components of the stem cell preparation in Example 4.
[0037] Figure 7 This is a quantitative detection diagram of the therapeutic effects of different components of the stem cell preparation in Example 4, wherein A: α-SMA staining, B: Collagen Ⅰ staining, C: Angiopoietin-1 staining.
[0038] Figure 8 The stem cell preparation in Example 4 reverses airway remodeling in severe asthma in vivo.
[0039] Fig. 9 The stem cell preparation in Example 4 restores lung function in severe asthma, wherein A: Penh, B: MVb. DETAILED DESCRIPTION
[0040] The present invention will be further described below in conjunction with the accompanying drawings and specific embodiments.
[0041] Example 1 Preparation of stem cell preparation
[0042] 1. Extraction of Mesenchymal Stem Cells
[0043] Male SD rats were killed by cervical dislocation and disinfected by soaking in 75% ethanol for 5-10 minutes. Epididymal fat or perirenal fat of rats was cut with sterile surgical scissors and quickly cut into pieces; tissue fragments were transferred to EP tubes, an equal volume of PBS (0.1M, pH 7.4) was added, type I collagenase was added after shaking, the tube was sealed, and digested at 37°C for 15 minutes; FBS was added to terminate digestion, and centrifuged at 1600rpm for 5 minutes; the supernatant was discarded, 2mL PBS was added to resuspend, insoluble matter was filtered through a 200-mesh sieve, the filtrate was collected, and centrifuged at 1600rpm for 5 minutes; the supernatant was discarded, 2mL red blood cell lysis buffer was added to lyse at room temperature for 2 minutes, 3mL PBS was added to mix, and centrifuged at 1600rpm for 5 minutes; the supernatant was discarded, 3mL PBS was added to resuspend, and centrifuged at 1600rpm for 5 minutes, and this step was repeated 2-3 times; the supernatant was discarded, 5mL DMEM containing 10% fetal bovine serum was added to resuspend, and the tube was transferred to a T25 culture flask for culture. It takes about 3 days for mesenchymal stem cells to adhere to the wall and appear spindle-shaped under the microscope. At this time, the culture medium needs to be replaced to remove foreign cells. When the primary mesenchymal stem cells grow to 80-90%, subculture is carried out.
[0044] 2. Preparation of Nanoparticles
[0045] In the following nanoparticle abbreviations: P stands for nanocarrier, including PLGA5000 -TK-PEG 2000 , PLGA 5000 -TK-PEG 2000 -Mal, V is Vactosertib, L is linifanib, A is A6 peptide, and MSCs are mesenchymal stem cells.
[0046] (I) Preparation of PVLA
[0047] Take PLGA 5000 -TK-PEG 2000 Solution 150 μL, PLGA 5000 -TK-PEG 2000 -Mal solution 100μL, VST solution 100μL, LFN solution 50μL, add to a 1.5mL centrifuge tube, vortex for 1min, and set aside; slowly drip the drug-carrier solution after vortexing into 40mL of stirring normal saline, one drop every five seconds, and stir for 5min after dripping; transfer 20mL of the suspension after stirring to a penicillin bottle, and crush it with an ultrasonic crusher at a power of 40W, ultrasonify for 2s, stop for 2s, and ultrasonicate for a total of 10min; add 20mL of the nanopreparation to a 50mL ultrafiltration tube, set the speed to 5000rpm / 3min, and concentrate to 4mL to obtain PVL; weigh 10mgA6 peptide, add it to the nanoparticle PVL solution, incubate overnight at 4℃ to obtain the nanopreparation PVLA.
[0048] (II) Preparation of PVL
[0049] Take PLGA 5000 -TK-PEG 2000 Solution 150 μL, PLGA 5000 -TK-PEG 2000 -Mal solution 100μL, VST solution 100μL, LFN solution 50μL, were added to a 1.5mL centrifuge tube, vortexed for 1min, and set aside; the drug-carrier solution after vortexing was slowly dripped into 40mL of stirring normal saline, one drop every five seconds, and stirred for 5min after dripping; 20mL of the suspension after stirring was transferred to a penicillin bottle, and crushed with an ultrasonic crusher at a power of 40W, ultrasonography for 2s, stop for 2s, and ultrasonication for a total of 10min; 20mL of the nanopreparation was added to a 50mL ultrafiltration tube, the speed was set to 5000rpm / 3min, and concentrated to 4mL to obtain PVL.
[0050] (III) Preparation of PV
[0051] Take PLGA 5000 -TK-PEG 2000 Solution 150 μL, PLGA 5000 -TK-PEG 2000-Mal solution 100μL, VST solution 100μL, were added to a 1.5mL centrifuge tube, vortexed for 1min, and set aside; the drug-carrier solution after vortexing was slowly dripped into 40mL of stirring saline, one drop every five seconds, and stirred for 5min after dripping; 20mL of the suspension after stirring was transferred to a vial, and crushed with an ultrasonic crusher at a power of 40W, ultrasonography for 2s, stop for 2s, and ultrasonication for a total of 10min; 20mL of the nanopreparation was added to a 50mL ultrafiltration tube, the speed was set to 5000rpm / 3min, and concentrated to 4mL to obtain PV.
[0052] (IV) Preparation of PL
[0053] Take PLGA 5000 -TK-PEG 2000 Solution 150 μL, PLGA 5000 -TK-PEG 2000 -Mal solution 100 μL, LFN solution 50 μL, were added to a 1.5 mL centrifuge tube, vortexed for 1 min, and set aside; the drug-carrier solution after vortexing was slowly dripped into 40 mL of stirring saline, one drop every five seconds, and stirred for 5 min after dripping; 20 mL of the suspension after stirring was transferred to a vial, and crushed with an ultrasonic crusher at a power of 40 W, ultrasonification for 2 seconds, stop for 2 seconds, and ultrasonication for a total of 10 minutes; 20 mL of the nanopreparation was added to a 50 mL ultrafiltration tube, the speed was set to 5000 rpm / 3 min, and concentrated to 4 mL to obtain PL.
[0054] like Figure 2 As shown, the particle size distribution of the nanoformulations PV, PL, PVL and PVLA prepared by the above method is around 150 nm.
[0055] 3. Preparation of MSCs / PVLA
[0056] Mesenchymal stem cells were cultured in T25 culture flasks at a density of 5 × 10 5 After culturing for 24 hours, the cells were co-cultured with the prepared nanoformulation for 2 hours to allow the CD44 receptor on the mesenchymal stem cells to undergo a biocoupling reaction with the A6 peptide on the nanoformulation, thereby obtaining MSCs / PVLA.
[0057] In order to characterize the binding of MSCs and PVLA, DiO-labeled fluorescent nanoparticles were first prepared using the method described in Example 1. MSCs in the logarithmic growth phase were plated in a confocal microplate at a density of 1×10 5After 24 hours of culture, the MSCs cell membrane was stained with DiD staining solution, washed with PBS three times, and diluted fluorescent nanoparticles were added. After 2 hours of culture, the cells were washed with PBS three times, fixed with 4% paraformaldehyde, and counterstained with DAPI staining solution for cell nuclei, and then placed under a laser confocal microscope for observation. Figure 3 As shown, after incubation of DiD-labeled MSCs with DiO-labeled fluorescent nanoparticles, it can be observed that the green fluorescence representing the nanoparticles and the red fluorescence representing the cell membrane overlap into yellow fluorescence, indicating that the nanoparticles are evenly distributed on the surface of the MSCs membrane and the two are successfully combined.
[0058] Example 2 Characterization of the accumulation of stem cell preparations in the lungs
[0059] 1. Construction of mice model of asthma airway remodeling
[0060] Female Balb / C mice (20±2g) aged 6 to 8 weeks were selected. The modeling of asthmatic mice was divided into two processes: sensitization and nebulization stimulation. During the sensitization phase, 50μg ovalbumin (OVA) and 1mgAl(OH)3 were intraperitoneally injected on days 0 and 1. Starting from day 21, 5% OVA was nebulized for 30 minutes three times a week using a nebulizer for a total of 6 weeks.
[0061] 2. Small Animal In Vivo Imaging
[0062] The stem cell preparation encapsulating DiR was prepared according to the preparation method of stem cell preparation described in Example 1. The following nanoformulations are abbreviated as follows: PA-DiR is a nanoformulation encapsulating DiR; MSCs-DiR is a mesenchymal stem cell labeled with DiR.
[0063] The asthmatic mice were divided into four groups for tissue fluorescence imaging experiments. DiR, PA-DiR, MSCs-DiR and MSCs / PA-DiR were injected into the tail vein at a dose of 2 mg / kg. After the end of the administration, live imaging was performed at 1h, 2h, 4h, 8h, 12h, 24h and 48h. At 24h, some mice were euthanized and the main organs (lungs, liver, heart, spleen, and kidneys) were dissected out for fluorescence imaging of isolated organs. Figure 4 As shown, compared with free DiR and PA-DiR, MSCs / PA-DiR can accumulate in lung tissue in large quantities, confirming the lung targeting of stem cell preparations.
[0064] Example 3 In vitro cell efficacy of stem cell preparations
[0065] 1. Cell scratch assay
[0066] Fibroblasts and pulmonary microvascular endothelial cells in the logarithmic growth phase were obtained, digested into single-cell suspensions and inoculated into 6-well plates, with approximately 1×10 cells per well.5 cells, add TGF-β or VEGF, place the well plate in a constant temperature incubator and culture for 24 hours, take a 10μL pipette tip from the cells, gently draw a straight line along the midline on the bottom of the plate, wash twice with PBS, and incubate the cells with PV, PL, PVL and PVLA (VST: 100μM, LFN: 25μM) diluted with serum-free culture medium, respectively. After incubation for 24 hours, fix the cells with 4% paraformaldehyde, and collect images of scars in different groups under an inverted microscope. Figure 5 As shown, after treatment with different preparations, cell migration was inhibited, among which the double-drug group had the best effect.
[0067] 2. Cell Migration Assay
[0068] Cell migration experiments were mainly conducted using Transwell chambers. First, pulmonary fibroblasts or pulmonary microvascular endothelial cells were seeded in the upper chamber of the Transwell chamber, with approximately 1×10 cells per well. 5 cells, add TGF-β or VEGF, add serum-containing culture medium to both the upper and lower chambers and continue to culture for 6 hours. Then replace the culture medium in the lower chamber with a serum-free culture medium, and add chemokine CXCL12800μL (10μg / mL) to the culture medium in the lower chamber for 24 hours, discard the culture medium, fix with 4% paraformaldehyde for 10 minutes, clean up the cells in the upper chamber with a cotton swab, rinse with PBS, and then stain with 0.1% crystal violet for 20 minutes, and then collect images of cell migration under a microscope. Figure 5 As shown, after treatment with different preparations, cell invasion was inhibited, among which the double-drug group had the best effect.
[0069] Example 4 In vivo efficacy of stem cells
[0070] 1. Construction of severe asthma model mice
[0071] The experimental animals were prepared as described in Example 2. The mice were treated with house dust mites intranasally at a frequency of three times per week from week 0 to week 6, and lipopolysaccharide was treated with the same method in week 7. The dose of each administration was 25 μg. Before administration, the mice were anesthetized and tilted at 45 degrees to ensure that the modeling drug reached the lungs.
[0072] 2. Analysis of the therapeutic effects of various components of stem cell preparations on bronchial airway remodeling in severe asthma
[0073] Airway remodeling model mice were constructed as described in Example 2, and PVLA, MSCs / PVA, MSCs / PLA and MSCs / PVLA were prepared as described in Example 1, and the therapeutic ability of different components of the prepared stem cell preparations on severe asthma was compared. The model mice were treated with PVLA, MSCs, MSCs / PVA, MSCs / PLA, MSCs / PVLA and budesonide (BUD), respectively. The dosing regimen was: 1.25 mg / kg LFN or 2×10 5 The BUD was administered intranasally at a dose of 3 mg / kg, three times a week for three weeks. The therapeutic effect of the mice was evaluated by immunohistochemistry. Figure 6 and 7 As shown, MSCs, MSCs / PVA, and MSCs / PLA have therapeutic effects on severe asthma after administration, and can reduce the expression of proteins such as α-SMA, CollagenⅠ and Angiopoietin-1 that are related to airway remodeling. However, there is no significant difference between the MSCs / PVLA group and the normal group after administration, but there is a very significant difference between the MSCs / PVLA group and the positive drug group, which is better than the positive control group.
[0074] 3. Analysis of the therapeutic effect of stem cell preparations on bronchial airway remodeling in severe asthma
[0075] For further verification, MSCs / PVLA were prepared as described in Example 1, and the model mice were treated with BUD and MSCs / PVLA, respectively, to compare the therapeutic ability of the prepared stem cell preparations on severe asthma. The dosing regimen was: 2×10 5 Stem cells were administered intranasally (in) once a week for two weeks. BUD was administered intranasally at a dose of 3 mg / kg three times a week for two weeks. For comparison, the present invention also used intravenous injection (iv), with a stem cell preparation dose of 2×10 5 The stem cells were administered once a week for two weeks.
[0076] After treatment, the lung function of mice was tested by WBP non-invasive lung function tester, and the therapeutic effect was evaluated by H&E staining, Masson staining and immunohistochemistry. Figure 8 and Fig. 9 As shown, the stem cell preparation used in the present invention can effectively inhibit airway remodeling and restore lung function in mice with severe asthma, with no significant difference compared with the normal group.
[0077] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. The use of Vactosertib or Linifanib and their combination in the preparation of drugs for the treatment of asthma.
2. The use according to claim 1, characterized in that: The asthma is severe asthma.
3. The use according to claim 1, characterized in that: The application of the stem cell preparation formed by the combination of Vactosertib and linifanib in the preparation of drugs for treating asthma.
4. The use according to claim 3, characterized in that: Stem cell preparations, including nano preparations and mesenchymal stem cells; wherein the mesenchymal stem cells are derived from adipose mesenchymal stem cells, bone marrow mesenchymal stem cells or umbilical cord mesenchymal stem cells; the nano preparations are made of PLGA 5000 -TK-PEG 2000 , PLGA 5000 -TK-PEG 2000 -Mal, A6 peptide (KPSSPPEECGPLGIAGQC), Vactosertib and Linifanib.
5. The use according to claim 4, characterized in that: The stem cell preparation is prepared according to the following steps: (1)PLGA 5000 -TK-PEG 2000 , PLGA 5000 -TK-PEG 2000 -Mal, Vactosertib, and Linifanib were dissolved in DMSO, mixed, and dispersed in 5% glucose solution; (2) the dispersion was ultrasonically disrupted and incubated with A6 peptide to prepare a nanoformulation; (3) The prepared nano preparation is co-incubated with mesenchymal stem cells to obtain a stem cell preparation.
6. The use according to claim 5, characterized in that: PLGA 5000 -TK-PEG 2000 , PLGA 5000 -TK-PEG 2000 -Mal was dissolved in DMSO at a concentration of 100-150 mg / mL, and Vactosertib and linifanib were dissolved in DMSO at a concentration of 10-15 mg / mL.
